Groupama Asset Managment Reduces Stake in DexCom, Inc. (NASDAQ:DXCM)

Groupama Asset Managment lessened its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 99.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 7,707 shares of the medical device company's stock after selling 2,843,849 shares during the quarter. Groupama Asset Managment's holdings in DexCom were worth $601,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Geode Capital Management LLC increased its stake in DexCom by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 9,993,698 shares of the medical device company's stock worth $775,256,000 after acquiring an additional 56,094 shares during the last quarter. Jennison Associates LLC boosted its position in shares of DexCom by 10.3% during the 4th quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company's stock worth $594,455,000 after purchasing an additional 710,858 shares during the period. Norges Bank acquired a new stake in DexCom in the 4th quarter valued at approximately $385,367,000. Charles Schwab Investment Management Inc. raised its position in DexCom by 3.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,825,206 shares of the medical device company's stock valued at $219,716,000 after purchasing an additional 91,051 shares during the period. Finally, Artisan Partners Limited Partnership lifted its stake in DexCom by 12.2% during the fourth quarter. Artisan Partners Limited Partnership now owns 1,853,565 shares of the medical device company's stock worth $144,152,000 after purchasing an additional 201,181 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company's stock.

Remove Ads

DexCom Stock Performance

Shares of NASDAQ DXCM traded up $6.15 during trading hours on Wednesday, reaching $66.84. The stock had a trading volume of 6,696,624 shares, compared to its average volume of 4,149,361. The firm has a market cap of $26.21 billion, a price-to-earnings ratio of 46.74, a PEG ratio of 2.30 and a beta of 1.50. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $141.25. The firm has a 50-day moving average of $77.74 and a 200-day moving average of $76.63. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Equities research analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have issued reports on DXCM. Morgan Stanley boosted their price target on shares of DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a research note on Friday, February 14th. Redburn Atlantic upgraded DexCom from a "neutral" rating to a "buy" rating and lifted their target price for the company from $85.00 to $115.00 in a report on Monday, February 3rd. Canaccord Genuity Group upped their price target on DexCom from $99.00 to $103.00 and gave the stock a "buy" rating in a report on Friday, February 14th. Citigroup lifted their price objective on DexCom from $101.00 to $104.00 and gave the company a "buy" rating in a research note on Tuesday, March 4th. Finally, Cfra Research upgraded shares of DexCom to a "hold" rating in a research note on Friday, March 21st. Five equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $99.82.

Insider Activity

In related news, EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the sale, the executive vice president now directly owns 83,526 shares of the company's stock, valued at $7,259,244.66. This trade represents a 2.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Kevin R. Sayer sold 32,498 shares of the business's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the completion of the transaction, the chief executive officer now directly owns 372,029 shares in the company, valued at $26,183,401.02. This represents a 8.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 105,009 shares of company stock valued at $8,044,178. Insiders own 0.30% of the company's stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.